Brazilian Prospective Hodgkin Lymphoma Registry
- Status
- UNKNOWN
- Phase
- N/A
Clinical Trials Related to Hodgkin Lymphoma
Related studies linked through entity extraction aliases.
A Study of Brentuximab Vedotin Combined With Nivolumab for Relapsed or Refractory Hodgkin Lymphoma
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Stem Cell Transplantation From HLA Partially-Matched Related Donors for Patients With Hematologic Malignancies
- Status
- COMPLETED
- Phase
- PHASE3
Reduced Intensity Chemotherapy and Radiation Therapy Before Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies
- Status
- COMPLETED
- Phase
- PHASE2
Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid Tumors
- Status
- RECRUITING
- Phase
- PHASE1
Thiotepa-based Conditioning for Allogeneic Stem-cell Transplantation (SCT) in Lymphoid Malignancies
- Status
- UNKNOWN
- Phase
- PHASE2
Multi-antigen CMV-MVA Triplex Vaccine in Reducing CMV Complications in Patients Previously Infected With CMV and Undergoing Donor Hematopoietic Cell Transplant
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Brentuximab Vedotin Plus AD in Non-bulky Limited Stage Hodgkin Lymphoma
- Status
- COMPLETED
- Phase
- PHASE2
Yoga to Alleviate Fatigue, Anxiety and Pain in Adolescents During Treatment for Lymphoma or Leukemia
- Status
- TERMINATED
- Phase
- NA
Study of Pembrolizumab (MK-3475) in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma (MK-3475-087/KEYNOTE-087)
- Status
- COMPLETED
- Phase
- PHASE2
Study of ADCT-301 in Patients With Relapsed or Refractory Hodgkin and Non-Hodgkin Lymphoma
- Status
- COMPLETED
- Phase
- PHASE1
Mocetinostat (MGCD0103) Plus Brentuximab Vedotin (SGN-35) in Patients With Relapsed or Refractory Hodgkin Lymphoma
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
CD8+ Memory T-Cells as Consolidative Therapy After Donor Non-myeloablative Hematopoietic Cell Transplant in Treating Patients With Leukemia or Lymphoma
- Status
- COMPLETED
- Phase
- PHASE2
Brentuximab for Newly Diagnosed Hodgkin Disease
- Status
- COMPLETED
- Phase
- PHASE2
Pembrolizumab After ASCT for Hodgkin Lymphoma, DLBCL and T-NHL
- Status
- COMPLETED
- Phase
- PHASE2
ACP-196 (Acalabrutinib) in Combination With Pembrolizumab, for Treatment of Hematologic Malignancies
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
GHSG-AFM13 An Open-label, Multicenter Phase II Trial With AFM13 in Patients With Relapsed or Refractory Hodgkin Lymphoma
- Status
- COMPLETED
- Phase
- PHASE2
Detection and Characterization of Residual Masses in Lymphomas
- Status
- COMPLETED
- Phase
- N/A
Brentuximab Vedotin as Consolidation Treatment in Patients With Stage I/II HL and PET Positivity After 2 Cycles of ABVD
- Status
- COMPLETED
- Phase
- PHASE2
Brentuximab Vedotin Associated With Chemotherapy in Untreated Patients With Hodgkin Lymphoma.
- Status
- COMPLETED
- Phase
- PHASE2